Placement of Shares
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Vectus Biosystems Limited has completed a placement to raise funds for its clinical trial work and other drug programs. The company received commitments from investors to raise a significant amount through the issuance of new shares and options. The placement was managed by Gleneagle Securities and is expected to enhance the company's financial position.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Vectus Biosystems Limited on 6ix
Earlier from Vectus Biosystems
- Appointment of Dr Tara Speranza as CEO & CTO
- VB4-P5 Renal Compound Transaction Settled
- Half Year Report & Appendix 4D
- Quarterly Activities & Appendix 4C Cash Flow Reports
- Response to ASX Query Letter
Later from Vectus Biosystems
All Vectus Biosystems news releasesFollow Vectus Biosystems into a list and get an email when it puts out news.
Follow Vectus Biosystems